Literature DB >> 6145436

Haemodynamic effects of ICI 118,587 in cardiomyopathy.

S Simonsen.   

Abstract

The haemodynamic effects of a new beta 1-adrenoceptor partial agonist, ICI 118,587, were studied in 10 patients with dilated cardiomyopathy and moderate to severe cardiac failure. Simultaneous right and left heart catheterisations were performed. Resting central haemodynamic indices were measured before and 15 min after an intravenous dose of 0.05 mg/kg and then 15 min after an additional intravenous dose of 0.15 mg/kg of ICI 118,587. Left ventricular performance was improved--as shown by significant increases in systolic left ventricular pressure, maximum rate of rise in left ventricular pressure (dP/dt max), and cardiac output and a decrease in left ventricular end diastolic pressure--without an undesirable increase in heart rate. The top of the dose response curve was reached after the lower dose. An important unwanted effect was seen in the most severely diseased patient, whose left ventricular systolic pressure, dP/dt max, and cardiac output decreased. This was probably due to the drug's antagonistic property supervening in this patient, who probably had high concentrations of circulating catecholamines. It is concluded that ICI 118,587 has a positive inotropic action and improves cardiac performance in patients with dilated cardiomyopathy and moderate cardiac failure, although care should be exercised when the drug is given intravenously in severe failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145436      PMCID: PMC481568          DOI: 10.1136/hrt.51.6.654

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  8 in total

Review 1.  Clinical pharmacology of digitalis glycosides.

Authors:  J E Doherty; J J Kane
Journal:  Annu Rev Med       Date:  1975       Impact factor: 13.739

2.  Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587.

Authors:  H Pouleur; M F Rousseau; P Mengeot; C Veriter; M F Vincent; L A Brasseur
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

3.  Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

4.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

5.  Comparison of dobutamine and dopamine in treatment of severe heart failure.

Authors:  J D Stoner; J L Bolen; D C Harrison
Journal:  Br Heart J       Date:  1977-05

6.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.

Authors:  N A Awan; K E Needham; M K Evenson; A Win; D T Mason
Journal:  Am Heart J       Date:  1981-02       Impact factor: 4.749

8.  Hemodynamic effects of intravenous prenalterol in severe heart failure.

Authors:  P C Kirlin; B Pitt
Journal:  Am J Cardiol       Date:  1981-03       Impact factor: 2.778

  8 in total
  8 in total

Review 1.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 2.  Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.

Authors:  H F Marlow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

4.  Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

Authors:  S J Virk; M K Davies
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

5.  Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.

Authors:  E Vigholt-Sørensen; O Faergeman; H M Snow
Journal:  Br Heart J       Date:  1989-11

6.  Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.

Authors:  L Barrios; J Geboers; J H Piessens; H de Geest
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.

Authors:  H F Marlow; F L Hine; H M Snow; H Pouleur; M F Rousseau
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  Renal effects of xamoterol in patients with moderate heart failure.

Authors:  H E Bøtker; H K Jensen; L R Krusell; E V Sørensen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.